Focused On-demand Library for Multiple C2 and transmembrane domain-containing protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q6DN14

UPID:

MCTP1_HUMAN

Alternative names:

Alternative UPACC:

Q6DN14; Q6DN13; Q8N2W1; Q8NBA2; Q96LX0; Q9H6E8

Background:

The Multiple C2 and transmembrane domain-containing protein 1, identified by the accession number Q6DN14, plays a pivotal role as a calcium sensor. It is essential for stabilizing normal baseline neurotransmitter release and is crucial for both the induction and long-term maintenance of presynaptic homeostatic plasticity. This protein's unique ability to sense calcium levels makes it a key player in neuronal communication and plasticity.

Therapeutic significance:

Understanding the role of Multiple C2 and transmembrane domain-containing protein 1 could open doors to potential therapeutic strategies. Its involvement in neurotransmitter release and presynaptic plasticity highlights its potential as a target in neurological disorders where these processes are disrupted.